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 ABSTRACT 
Objective: 
 To compare the maternal and fetal outcome in severe PIH patients 
presenting between 30-34 weeks managed conservatively till 34 weeks 
and terminated actively between 30 -34 weeks 
Study design: 
 It was a comparative study conducted at Govt. 
MohanKumaramangalam Medical College, Salem with a sample size of 
100 patients who had severe preeclampsia between 30 to 34 weeks. 
Methods: 
Patients who fulfill the inclusion criteria and exclusion criteria 
were selected for the study. History, examination and investigations were 
done. Details of the plan of treatment and the indication and mode of 
termination are noted. Maternal and fetal follow up done upto discharge / 
death. 
 
 
 
 
 Results: 
• Mostly are in ages between 21-30 years 
• Mostly primi (62%) 
• Mean gestational age = 31 years 
• 35% women had past history of preeclampsia 
• 16% had family history  
• 32 women had maternal morbidity 
• There was no maternal death in our study 
• Most women in active management delivered by vaginal delivery 
• Termination of pregnancy in expectant management  was due to 
maternal indication in 58% and fetal in 42% 
• 29% perinatal death was recorded in our study 
• Mean birthweight was 1.8 kg in expectant group and 1.6 kg in 
active group 
 
 
 
 
 
 Conclusion: 
Severe preeclampsia is associated with significant maternal and fetal 
complications. Decision regarding pregnancy termination is to be taken 
on the grounds of both maternal and fetal factor. The expectant 
management of severe preclampsia results in a good fetal outcome for 
1. Higher birth weight 
2. Lower perinatal mortality 
3. Lesser neonatal complications 
But this must be weighed against the risk of maternal morbidity. Hence 
they should be carried out only in tertiary care centres 
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INTRODUCTION 
Preeclampsia is a multisystem disorder involving placenta, blood, 
cardiovascular, liver, kidney and neurovascular system, occurring 
exclusively during pregnancy etiology of which is unknown. 
Approximately 5-7% of pregnancies are affected. It is an important cause 
of morbidity and mortality in both the mother and fetus. 
Preeclampsia is described as a rise in blood pressure and 
proteinuria which is of new onset, occurring after 20th week of gestation. 
It is described as severe preeclampsia if there is end organ damage and 
substantial increase of blood pressure and proteinuria or the occurrence of 
symptoms. Preeclampsia is considered early onset if elevation of blood 
pressure and proteinuria occur before 34th week of pregnancy. 
Hypertension and its complications is ranked third as a leading cause of 
maternal mortality, causing over 17% of maternal deaths. Women still die 
from pre – eclampsia and eclampsia even in developed nations. 
There is increased risk of abruptio placenta, acute renal failure, 
cardiovascular and cerebrovascular complications, DIC and even death. 
So, early diagnosis and close monitoring in preeclampsia is important for 
preventing its complications. 
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In early onset severe preeclampsia, there is progressive 
deterioration in the condition of the mother and also high morality in the 
fetus in perinatal period. Delivery of the fetus is considered to be the only 
way for reverting all these complications. Hence termination of 
pregnancy is needed if fetal distress occurs in case of multi organ 
dysfunction or if the gestation age reaches 34 weeks. But, early 
termination causes high perinatal morbidity and mortality in fetus due to 
prematurity. But expectant management to prolong pregnancy can be 
harmful to the mother. Hence, potential benefits of the fetus should be 
weighed against the potential dangers that may occur to the mother. 
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AIM OF  THE STUDY 
AIM: 
To compare the maternal and fetal outcome in severe PIH 
patients presenting between 30-34 weeks managed conservatively 
till 34 weeks and terminated actively between 30 -34 weeks 
OBJECTIVES 
Primary objectives: to compare the maternal outcomes like 
abruptioplacenta, HELLP syndrome, eclampsia, PRES, Acute 
kidney injury, pulmonary edema in active and expectant group. 
To compare the fetaloutcomes like Still birth, perinatal death, birth 
weight, apgar scores, admission to New born rate. 
Secondary objectives include reason for termination 
,duration of prolongation of pregnancy in expectant group, 
comparison of mode of delivery in both the groups. 
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REVIEW OF LITERATURE 
HISTORICAL ASPECTS: 
• Eclamptic convulsions dates back to 4000 years which was 
recognized in Indian, ancient Chinese, and Greek literature.  
• Around 400 BC, Hippocrates stated that headache with convulsions 
during Pregnancy was to be considered bad.  
• Bossier de saurages (1739)coined the term“Eclampsia” 
• John Lever(1843) reported that Proteinuria was specific to the Pre-
eclampsia condition. 
• Eclamptic hypertension was discovered by Vasquez and Nobcourt 
(1897). 
• Chesley (1984) said that Sensory stimuli were decreased by 
keepingpatients is quiet dark room. 
• Horn (1906) was the first to use magnesiumsulphate on  pre-
eclampsia and Eclampsia. 
• Several studies demonstrate that magnesium sulphate is superior 
over other anticonvulsants. 
• In 1967, Robertson and Brosens described structural changes ofthe 
utero placental unit in pre-eclampsia. 
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• Sibai  and Barten (2007) management of severe preeclampsia 
guidelines 
MAGNITUDE: 
50% of women with severe pre-eclampsia present before 34 weeks 
ofgestation. Delivery is the only way to relieve symptoms. It may be for 
maternal or fetal reasons. 
CLASSIFICATION: 
National High Pressure Education program  classification 
• Gestational Hypertension 
• Pre eclampsia 
• Eclampsia 
• Superimposed Pre eclampsia 
• Chronic Hypertension 
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DEFINITIONS 
PRE-ECLAMPSIA 
Pre-eclampsia is defined as rise in systolic blood pressure of 140mmHg 
or higher or diastolic blood pressure of 90 mmHg or higher at 2 different 
occasions atleast 6 hours apart thatdevelops forthe first time in pregnancy 
after 20 weeks of gestation accompanied by proteinuria. 
Proteinuria is defined as urinary protein of 300mg or more per 24hours or 
persistent 30 mg/dL in a random sample. 
SEVERE PRE-ECLAMPSIA: 
Severe pre-eclampsia is defined as hypertension (diastolic blood 
Pressure110 mm Hg or higher) with proteinuria (5gm or higher in 24 
hours urinesample or  more than 3+ on a dipstick). 
EARLY ONSET SEVERE PRE- ECLAMPSIA: 
When severe pre- eclampsia develops prior to 34 weeks of 
Gestation[25] . 
It complicates in 5-8% of pregnancy and is a major cause for maternal 
and perinatal morbidity and mortality[1,2]. 
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ACOG CRITERIA FOR SEVERE PREECLAMPSIA 
Preeclampsia is a clinical diagnosis encompassing three elements 
(committee on obstetric hypertension in pregnancy ACOG 1996) 
1) New onset hypertension (defined as a blood pressure 
consistently more than 140/90 mm of Hg in previously 
normotensive women) - according to the latest American 
college of obstetricians and gynecology bulletin  
2) New onset proteinuria defined as more than 300mg /24hrs or > 
2+ on a clean catch dipstick in the absence of urinary infection 
3) New onset significant independent edema.  
4) The diagnosis of PREECLAMPSIA should be made only after 
20 weeks of gestation. 
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Conventional mercury sphygmomanometry is still the gold standard 
device for blood pressure measurement. Blood pressure should be 
measured with the mother seated or reclined at 45º, with her feet on the 
ground or well supported, and her arm at the level of heart. The right arm 
should be used with the cuff of the appropriate size. Electronic blood 
pressure monitors may underestimate the true pressure. 
 
POSITIONING OF PATIENT FOR BP RECORDING 
Nowadays it has been recommended that korotkoff phase V be used as a 
measure of diastolic pressure[3] 
1. K4/K5 difference is smaller in hypertensive than in normotensive 
pregnant women. 
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2. K5 which is close to the actual intra-arterial pressure, 
physiologically more accurate, is more reliably detected and is 
reproducible. 
3. K4 has limited reproducibility [4] 
 
Pre eclampsiais classified as either “mild” or “severe”. 
 No classification of  moderate Preeclampsia exists. 
 
10 
 
SEVERE PREECLAMPSIA (ACOG) 
A diagnosis of severe Preeclampsia should be considered in women with 
new onset proteinuric hypertension and one or more of the following 
complications. 
I. Blood pressure ≥ 160/110 mmHg on 2 different occasions at 
least 6 hours apart. 
II. Proteinuria (5g or more in 24hr urine) 
III. Oliguria <500ml in 24hrs 
IV. Cerebral and visual symptoms like blurred vision, altered 
mental status and severe headache. 
V. liver capsule distention  
VI. Pulmonary Edema or cyanosis 
VII. Thrombocytopenia (<1 lakh platelets / mm3 ) 
VIII. Hepatocellular injury  
IX. Fetal growth restriction 
 
 
 
 
11 
 
THEORIES ABOUT CAUSES OF PREECLAMPSIA 
1. Abnormal trophoblastic invasion 
Normal implantation causes remodeling of spiral arterioles in 
decidua basalis. Endovascular trophoblasts normally replace the tunica 
intima and tunica muscularis layers and enlarge the diameter of vessel. 
But in pre eclampsia there is immunological resistance to invading 
trophoblast by maternal immune system and only the endometrial vessels 
get lined by trophoblasts and results in inadequate trophoblast invasion of 
myometrial spiral arterioles.this narrow lumen impairs the placental 
blood flow and lead to release of placental debris into circulation and 
induce a systemic inflammatory response[29] 
Abnormal trophoblastic invasion of spiral arterioles – secondary 
invasion 
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2. Immunological mechanism – BARDEQUEZ[5] 
Based on incompatibility at the feto-maternal interface. In pre 
eclamptic women , there is reduced level of immunosuppressant HLA G, 
increased Th1 and change in Th1/Th2 ratio. This enhances 
immunologically mediated inflammatory reaction.   
3. Genetic predisposition – CHESLEY & COOPER 1986[6] 
Susceptibility is by both single gene and multifactorial inheritance. 
Angiotensin gene variant T235 is associated with increased incidence. 
inpreeclamptic patients there is higher incidence of  mutation of factor V 
Leiden 
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4. Increased pressor response to angiotensinogen II – ABDUL 
KAREEM 1961 [7] 
Normally pregnant women , on vasopressor infusion, develop 
refractoriness. But pre eclamptic women are more reactive to 
noradrenaline and angiotensin II which results in gestational hypertension  
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5. Altered vasoactive factors: VOLHARDT 1918 [8] 
(A) Endothelin- 1. A potent vasoconstrictor produced by endothelium. 
ET-1 is elevated in pregnancy. In preeclampsia it is elevated to an even 
higher level.[32] 
(B) NITRIC OXIDE:- A potent vasodilator is  decreased in preeclamptic 
women.[9]. This causes increased MAP, reduced heart rate.  
(C) Reversal of PGI2 to TXA2 and vit.E ratio [10] 
(D) Vasoactive maternal factor (VMF) is found to cause the endothelial 
changes in the pathophysiology of PIH. 
6. Oxidants and Antioxidants 
Hubal et al [11] have confirmed that Preeclampsia may have its 
origin in a disturbed oxidation mechanism. Normally equilibrium is 
maintained by auto oxidants. With increase in severity of Preeclampsia, 
lipid peroxidase increases and auto oxidants decreases. Vit E lipid 
peroxidase is responsible for endothelial damage. 
7. Endothelial dysfunction: HAYMAN & ASS 2000[12] 
Activation of maternal leucocytes result in endothelial cell 
dysfunction. Endothelial cell dysfunction is a major factor in the 
pathogenesis of pre- eclampsia. TNF – α and interleukins release reactive 
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oxidation species and free radicals that lead to lipid peroxidase formation, 
which in turn generate toxic radicals and injure endothelial cells resulting 
in placental oxidative stress.Banker and Coll 1995 have shown that, in 
preeclampsia, BEGF levels are increased which activate endothelial cells 
and release inflammatory substances.[13]Recent studies show that raised 
level of fmstyrosine kinase , TGF  beta in association with endothelial 
dysfunction. 
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8. Placental proteins: 
HCG, Corticotropin releasing factor, Activin A, Inhibin A are said to play 
an important role. 
9. Dietary deficiency:  
DAWSON, KELLY & Coauthors Mac Gillivray viewed the evidence 
for a role of dietary deficiency in pathology of Pre eclampsia. It was 
found that when calcium is low in ECF, there is increase in amount of 
ionic calcium entering cell wall making vascular smooth muscle more 
sensitive to excitation. 
10. Hyperhomocystinemia: COLLER ET AL 
Retroplacental infarcts elevate the levels of circulatory homocysteine. 
This is due to atherosis formed at placental site. Elevated levels damage 
endothelium by H2O2 generation. 
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RISK FACTORS 
Maternal and paternal genetic factors increase the risk of preeclampsia. 
Pregnancy associated: 
- Chromosomal abnormalities 
- Hydrops fetalis 
- Hydatidiform mole 
- Multigravida 
 
Maternal specific: 
- Primi parity 
- Age < 20 &> 35 Yrs. 
- Family history of pre-eclampsia. 
- pre-eclampsia in previous pregnancy 
- BMI > 35 
- Gestational diabetes. 
- Chronic hypertension. 
- Nephropathy. 
- Thrombophilias. 
 
Paternal Specific: 
- New paternity 
- Previously fathered a pre-eclampsia pregnancy in another woman. 
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PATHO PHYSIOLOGICAL CHANGES 
PRIMARY LEVEL: 
Pre eclamptic changes in placenta and its arterioles are due to: 
• inadequate  trophoblastic infiltration of arterial walls  [33] 
• Acute atherosis [34] 
• Magnitude of defective trophoblast invasion of spiral arterioles 
correlated with severity of hypertensive disorder. 
• Lipid accumulates first in myometrial cells and then in 
macrophages[35] 
 
SECONDARY LEVEL 
I.Renal system 
• Decreased renal blood flow 
• glomerular capillary endotheliosis causing glomerular function 
• Proteinuria is a result of advanced disease with poor prognosis[36] 
• Urinary sediments [37] 
• Decreased uric acid clearance ( Chesley& Williams 1945 ) 
• Increased tubular reabsorption resulting in Hypocalciuria[38] 
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GLOMERULAR CAPILLARY ENDOTHELIOSIS 
II. Cardiovascular system 
• Hemodynamic Changes: 
a) decreased Cardiac preload due to generalized vasospasm[14] 
b) increased Cardiac after load due to increase in vascular 
resistance. 
c) reduced MAP due to increase is peripheral vascular resistance. 
• Hematological Changes 
a) Thrombocytopenia – probably immunologically mediated or 
because of increase in platelet deposition at the endothelial damage 
site.  
b) Hyper coagulation is pre-eclampsia is due to 
• Increased platelet aggregation   
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•. Increased activity of intrinsic factors. 
• Increased thrombin – Anti thrombin ratio. 
• Decreased fibrinogens and anti thrombin III 
C) HELLP SYNDROME: 
Hemolysis- elevated LDH levels, fragmented RBC  in peripheral 
smear, decreased serum haptoglobulin 
Elevated AST or ALT more than 70 IU / L 
Platetet count less than 1 Lakh 
MISSISSIPPI CLASSIFICATION OF HELLP: 
Class I - platelet count less than 50000 
CLASS II - platelet count - 50,000 - 1,00,000 
CLASS III- Platelet 100000- 150000 , elevated AST 
III. Endocrine changes: 
• Suppressed renin- angiotensin - aldosterone axis 
• Increased renin levels 
• Decreased angiotensin II and aldosterone 
• Atrial natriuretic peptide is increased in women with preeclampsia 
increased sodium retention [39] 
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IV. Fluid Changes: 
Endothelial damage leads to extra cellular fluid volume increases 
which results in proteinuria and edema  
V. Hepatic changes: 
• Elevated liver enzymes 
• Raised hepatic artery resistance 
• Periportal hemorrhagic necrosis 
• HELLP syndrome 
 
Subcapsular hemorrhage in liver 
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PERIPORTAL NECROSIS 
 
VI. Coagulation changes 
• Intravascular coagulation 
• Prolonged thrombin time 
• Decreased platelet aggregation 
• Reduced antithrombin III 
• Fragmentation haemolysis [40] 
• Thrombophilias 
TERTIARY CHANGES 
Tertiary systemic effects of preeclampsia secondary to 
decompensationwhichpresents as one of the following features. 
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1. Abruptio placenta: 
Premature separation of placenta.incidence 1 in 80 deliveries, most 
commonly associated with severe preeclampsia.haemorrhage into 
decidua basalis  of placenta.bleeding in abruption can be 
concealed, revealed or both.release of thrombolastin ,bleeding in 
myometrium - couvelarieuterus.severe abruption can resultin PPH, 
DIC, AKI, shock.fetal complication like IUD can occur in grade II 
/ III 
 
2. Neurological – Eclampsia, headache, scotoma, cerebral 
hemorrhage 
Eclampsia : extremely severe form of preeclampsia.characterised 
by sudden onset of GTCS or coma in pregnancy / postpartum 
period. most occur in the last trimester.occurence before 28 weeks 
carry worse prognosis. Frequency of eclampsia. 
AP eclampsia - 38- 53% 
IP  eclampsia - 15 - 20% 
PP eclampsia - 11 - 40% 
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Pathophysiology is abnormal cerebral autoregulatory response 
leading to vasoconstriction, ischaemic changes generating electrical 
discharges  that generalise and cause convulsions.case fatality rate is 
approximately 1.8 %; morbidity - 35%.Perinatal mortality occurs in 5- 
12% 
Management of eclampsia : 
Control of convulsion : Mgso4 therapy 
Control of hypertension 
Delivery of the fetus  
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3. DIC 
4. Ophthalmic- Corneal edema, retinal detachment 
5. Pulmonary edema:  
6. ARDS 
7. Hepatic rupture  
 
DISSEMINATED INTRAVASCULAR COAGULATION 
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RETINAL DETACHMENT 
 
 
             RETINAL DETACHMENT – FUNDAL CHANGES 
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Uterine Artery Doppler Velocimetry: 
Trophoblastic invasion of spiral artery is reduced in pre eclampsia. This is 
predicatble by using Doppler study. Increased uterine artery velocimetry 
in Doppler study act as indirect evidence for the decrease in trophoblastic 
invasion.increased artery flow resistance is depicted by an exaggerated 
diastolic notch in the abnormal wave form. 
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PREDISPOSING FACTORS OF PREECLAMPSIA 
1. Age : 
Patients<20 and >30 years showed increased incidence of preeclampsia. 
In patients > 35 years Pre-eclampsia accounts for over 40% of pre-mature 
deliveries with increased of risk of low birth weight and Small for 
gestational age babies 
2. Parity : 
Incidence of preeclampsia is 11.9% in primi and 4.7% in multigravida. 
(according to Clinical obs and gyn).  The incidence is about 24% in new 
paternity multipara because they have shorter period of Sperm exposure 
preceding conception. 
3. Race 
Muslims, jews&arabs have higher incidence of preeclampsia 
[Davis et al 1970] 
Africoamericans also have higher incidence. 
4. Social status: 
Women from low social economic status are said to have higher 
incidence of PIH, PE, Eclampsia. But Baird and colleagues 
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1969, in their study said that the five socioeconomic status does not show 
any difference in incidence. 
5. Previous H/O preeclampsia 
a. higher risk of  preeclampsia is seen in subsequent pregnancies 
when there is history of severe pre eclampsia associated with low 
birth weight in the previous pregnancies 
b. maternal age and interval between pregnancies is directly 
proportional to the risk of preeclampsia . 
6. Family history 
 Family history of eclampsia and pre eclampsia have a impact on 
the current preganacy.  Risk is three times in pre eclampsia and four times 
in severe pre eclampsia. 
[41] 
7. Urinary tract infection:  
UTI results in increased production of inflammatory products such as  
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cytokines, free radicals and proteolytic enzymesthat causes endothelial 
dysfunction[42] 
8. Pregnancy associated: Early onset 
a. Twin gestation: Incidence of PE 25.3% due to hyperplacentosis with 
increased secretion of placental hormone and associated placental 
ischemia and immunological reaction. 
b. Molar pregnancy:Incidence of PE is 70% in women with rapidly 
growing moles.there is no increased incidence of PE with slowly growing 
moles. 
c. Congenital malformations: the risk of developing PE is 35% due to 
placentomegaly in triploidy 
d. Hydropsfetalis:hyperplacentosisrises the risk. 
9. Smoking: 
Smoking  causes a significant reduction in HCG andestradiol level due to 
direct effect on the placental function 
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OUTCOME 
Maternal Outcome: 
Women with Severe Pre-eclampsia are at increased risk for 
abruptio placenta, DIC, cerebral haemorrhage, acute renal failure, 
pulmonary edema and circulatory collapse[15]. 
Al –Mulhim et al reported that the commonest complication to be 
abruptio placenta. 
Perinatal Outcome: 
Perinatal outcome depends on: 
1. Gestational age at the time of delivery. 
2. Gestational age at the onset of pre eclampsia. 
3. Present of multiple gestation. 
4. Presence of other medical disorders. 
5. Severity of the disease. 
In a study, Odegard et al[16] compared 307 live singleton babies 
born to pre eclamptic women to 619 controls. Pre-eclampsia and severe 
preeclampsia were associated with 5% and 12% reduction in birth weight 
respectively.  birth weight was 23% lower than the expected birth weight. 
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Magee et al[17] in a multi centric retrospective study found out 
that 16% of pre-eclampsia pregnancies being complicated by birth weight 
less than third percentile. 
Very low birth weight (BW < 1500 grms) and extremely low birth 
weight (BW< 1000 grms) babies often require re-admission to hospital in 
the first two years of life for respiratory infections[18] 
PULMONARY EDEMA 
It Is A Common Complication of severe pre eclampsia. The 
clinical signs and symptoms include basal rashes over limb folds, 
respiratory distress, hypoxia and pulmonary edema. 
The fluid overload in postpartum period which causes edema 
expansion and left ventricular failure results in pulmonary edema in 
preeclamptic patients. Typically the patients are with no prior history of 
heart disease, normal ecg, no cardiomyopathy on echo or chest xray 
TREATMENT:  
Propped up position, back rest, nasal o2 administration, fluid restriction 
Diuretics: frusemide 40mg iv q 6hourly 
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CPAP may be used in severe condition of pulmonary edema with 
respiratory distress to sshift the fluid to interstitial compartment and thus 
into capillaries. 
Frusemide act by profuse diuresis and thus reducing the 
intravascular fluid volume. Central venous pressure monitoring may be 
necessary in patients with co morbid illness. 
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ABRUPTIO PLACENTA 
Abruption is one of the most leading cause of antepartum 
hemorrhage in patients with pre eclampsia. The premature separation of 
normally situated placenta prior to the delivery of the fetus occurs mostly 
in pre eclamptic patients. 
It is indicated by antepartum hemorrhage typically associated with 
uterine tenderness. 
Leading into the decidua basalis may be concealed or revealed 
externally concealed hemorrhage in mostly diagnosed after delivery as 
retroplacental clot. 
The degrees of placental separation may be 
1. Mild: concealed hemorrhage with retrospective diagnosis 
2. Moderate: live fetus with signs and symptoms of abruption present 
3. Severe: dead fetus with features of coagulopathy 
Management mainly aims at preventing and reducing complications 
• maternal : DIC, hypovolemic shock, AKI 
• fetal: low birth weight, preterm labor, fetal hypoxia 
conduct of normal labor is possible with continuous fetal heart rate 
monitoring. normal labor is preferably carried out in tertiary care centre 
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after securing 2large bore IV cannula, bed side clotting time assessment, 
drawing blood and reserving adequate blood . 
Experienced neonatologist may be needed for resuscitation of the baby. 
Strict monitoring of maternal vitals with special importance to pulse, 
urine output and BP. 
Caesarean may be taken up in conditions like fetal distress, failure of 
progress of labor. 
Couvalaire uterus is bleeding into the myometrial layers of the uterus 
which leads to release of thromboplastins causing DIC. Uterine laxicity 
leading to atony of uterus causing further bleeding is promptly interfered. 
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USG OF PLACENTA ABUPTION 
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FETAL OUTCOMES 
 
IUGR BABY 
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GROWTH CHART 
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EXPECTANT MANAGEMENT 
RCOG AND ACOG RECOMMENDATIONS 
AIM:- 
To prolong pregnancy in severe preeclampsia women remote from term 
in order to improve perinatal outcome without increasing maternal 
morbidity or mortality. 
PLACE:- 
Management is best carried out  in a tertiary care setting. Candidates 
depend on a number of factors like maternal and fetal conditions as well 
as gestational age[19]. Expectant management cannot be done in 
gestational age <26 weeks as there is increase in perinatal & maternal 
morbidity and mortality.  
PROTOCOL  FOR EXPECTANT MANAGEMENT 
1. All patients are observed in Labour room for at least24 hours to 
determine their eligibility for expectant management. 
2. Intravenous magnesium sulphate  for seizure prophylaxis for 
selected patients.  
3. Fetal outcome is improved by glucocorticoid administration. 
4. Antihypertensive for BP control. 
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5. Complete Blood count, Platelet count, urine protein, serum uric 
acid, serum creatinine, AST, LDH. 
6. Limited oral intake for the first 24 hours and intravenous fluids at 
the rate of 100 –125 ml/ hr within 24 hours. 
MANAGEMENT OF SEVERE HYPERTENSION- 
ANTIHYPERTENSIVE THERAPY 
RCOG guidelines- recommend ANTIHYPERTENSIVE if systolic 
BP more than 160, diastolic more than 110. 
LABETOLOL:  
First line drug in both acute severe hypertension, maintenance 
treatment. 
Combined alpha and beta adregenic blocker 
Available in both oral and parenteral forms. 
Ratio of blockade is 1 : 3 in oral , 1: 7 in parenteral 
Avoided in asthmatics, heart failure 
Oral treatment- 100 to 400mgevery 6- 12 hours 
For intermittent iv dose- 20 mg bolus followed by 40- 80 mg every 
20 minutes. Maximum dosage 220 mg per cycle 
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Continuous iv use, 500 mg Labetolol added to 400 NS, administered at 20 
mg / hour.Dose doubled or halved according to BP. Maximum dose- 220 
mg / hr 
NIFEDIPINE:  
Calcium channel blocker 
Reduces peripheral vascular resistance, tocolytic agent by blocking 
influx of calcium ions in vascular smooth muscle cells. Initial dose of 10 
mg repeated after 30 mins according to BP 
45 
 
Rapid onset of action, half life - 30 mins 
 
Others: 
 Alpha methyl dopa- not recommended in severe preeclampsia due 
to delayed onset of action. 
 Diazoxide may result in sudden hypotensive response, not 
recommended 
 Sodium nitroprusside to gradually decrease BP. Possibility of fetal 
toxicity with prolonged use because of cyanide content. 
 Hydralizine - acts directly on the arteriolar smooth muscle thereby 
reducing PVR. Maternal tachycardia, late  decelerations in CTG 
due to decrease in uteroplacentalflow are the disadvantages.  
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ROLE OF STEROIDS: 
Dexamethasone 6mg  im 4 doses, 12 hours apart is recommended 
Betamethasone 12 mg im 2 doses, 24 hours apart. 
Studies show that dexamethasone is better than betamethasone in Indian 
preparation. 
 
Neonatal complications like RDS  , death, IVH are reduced if STEROIDS 
administered prior to delivery 
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MGSO4 TREATMENT 
Prevention of seizures by MgSo4 regimen is widely used. Strict 
monitoring of urinary output, patellar reflex, respiratory rate, and 
saturation is needed.  
Disappearance of patellar reflex - First sign of impending MgSo4 
toxicity is which is handled by administration of 10ml of 10% calcium 
gluconate, used as an antidote. 
Pritchard regime:  
• Most preferred regime 
• Loading dose: 20 ml of 20% MgSo4 slow IV and IM 50% MgSo4 
10grams – 5 grams each buttock deep IM. 
• Followed by 10 ml of 50% MgSo4 deep IM (5ml on each buttock) 
every 4 hours until 24 hours after delivery or onset of  last episode 
of last seizure whichever occurs later. 
Other management protocols include: 
• daily weight chart 
• I/O chart 
• Umblical and middle cerebral artery Doppler twice every week 
• USG- for fetal growth every 2 weeks 
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Expectant Management in IUGR:  
Studies have showed that in servere pre-eclampsia at 24 – 33 weeks 
IUGR is also associated with high risk of fetal mortality but does not 
result in maternal complications[20] and this may benefit from 
prolongation of pregnancy beyond 48 hours which is required for action 
of steroids. 
Expectant management in HELLP Syndrome: 
Studies show that women with HELLP syndrome should not be 
expectantly managed. Vaginal or caesarean delivery should be pursued. 
Concurrently antenatal steroids may be given. 
GUIDELINES FOR AGGRESSIVE TREATMENT: 
1. All patients should be observed in labour room. 
2. IV magnesium sulphate given to selected patients for seizure 
prophylaxis. 
3. Glucocorticoid therapy given for improving fetal outcome followed by 
delivery in 48 hrs. 
4. Antihypertensives for BP control, blood investigations done - 
Complete Blood count, Platelet count, urine protein, serum uric acid, 
serum creatinine, AST, LDH 
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5. USG for fetal well-being .Then labour is induced either by misoprostol 
or cerviprime may or may not be augmented with syntocin infusion 
GUIDELINES FOR MANAGEMENT 
FETO – MATERNAL MONITORING: 
• Initially, blood pressure should be measured for every 15 minutes 
till stabilized and then to be checked every 30 minutes. 
• Later, measure BP at least four times per day 
• Daily weight chart, urine albumin chart 
• Ophthalmic evaluation for retinal fundus changes 
• CBC with platelet count,AST,ALT, LDH are repeated every other 
day 
• If platelet count is above 1 Lakh cells/dL, clotting studies are not 
required. 
• Input and output charting is essential in monitoring the fluid 
balance,especially in the immediate postpartum period 
• To have vigilant watch for imminent symptoms and signs like 
headache, blurring of vision, vomiting, epigastric pain, decreased 
urinary output. 
• Daily fetal movement count 
• Antihypertensive treatment 
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• Steroids- InJ. Dexamethasone  6 mg , 4 doses over 48 hrs  
 
 
ASSESSMENT OF FETUS: 
Fetal Monitoring is done by fetal heart rate monitoring 
withcardiotocographythat gives information regarding fetal wellbeing. in 
women in labour, Continuous fetal monitoring should be 
done.furtherassessmentis done by 
• NST weekly to daily depending on liquor status, fetal growth. 
• Fetal biometry   every 2 week 
• liquor volume twice every week 
• umbilical and cerebral Doppler once in 2 weeks 
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Umbilical artery showing normal SD ratio 
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Absent diastolic flow Doppler 
 
 
Reversal of diastolic flow doppler 
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Dopplerevaluation using absent or reversed umbilical artery diastolic 
flow improves fetal outcome[43]. Delivery time can be measured by 
continuous serial monitoring.Rate of perinatal death is about 33 % in 
reversal of diastolic flow. 10 % in absent diastolic flow. 
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TERMINATION OF PREGNANCY 
Termination is needed is the following conditionsn( criteria to 
INTERRUPT EXPECTANT MANAGEMENT) 
FETAL 
• Non reassuring fetal surveillance 
• Abnormal Doppler changes 
• Severe IUGR 
• Oligohydramnios 
• Fetal death 
• Biophysical profile less than or equal to 4 
Maternal 
• Abruptio placenta 
• Progressive detoriation of liver and renal function 
• Platelets < 1 lakh 
• Signs and Symptoms of imminent eclampsia 
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MODE OF DELIVERY: 
There are no randomized trials for comparing the ideal method for 
delivery in women with pre-eclampsia. Vaginal delivery should be 
attempted for all women with mild pre-eclampsia and for most women 
with severe pre-eclampsia, provided that there is no other indication for 
caesarean section[21]. Pre-eclampsia per se is not an indication for 
caesarean section. 
 
INTRAPARTUM MANAGEMENT 
Preeclamptic women are at higher risk of developing convulsions during 
labour. Highest being is seen in severe preeclampsia remote from term, 
and those with cerebral manifestations, HELLP syndrome. 
1. Hence if not initiated with MgSO4, it should be started in labour in 
selected cases. 
2. Once cervix becomes favourable for, oxytocin augmentation may be 
given. 
3. If it is unripe, Caesarean section should be considered because of 
higher incidence of abruption, fetal distress and other complications. 
4. ANALGESIA 
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• Provided by intermittent use of 25-50 mg of pethidine (parentral) 
or segmental epidural analgesia. 
• Local infitration in vaginal delivery. 
• Continuous epidural or balanced GA used for caesarean 
5. Input and output monitoring  
• Hourly urine output. 
• restricted Fluid intake to 150 ml / hr. 
• If oliguria (<100ml per 4 hrs), fluids & MgSO4 adjusted 
accordingly. 
6. Antihypertensive therapy. 
Goal is to maintain systolic BP 140 –150 and diastolic 90-100 mm Hg. 
mean arterial pressure should not be reduced by more than 20% from 
baseline. 
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POSTPARTUM MANAGEMENT 
1. Intensive monitoring done for 2-4 days. Vitals, input output monitoring 
and reflexes are noted. 
2. BP control 
3. Prophylactic anticonvulsant are not given. 
4. Patient is seen weekly until her BP returns to normal without 
medications. 
5. If change does not occur by 6 weeks, hypertension work up is made 
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MATERIALS AND METHODS 
 
TYPE OF STUDY: COMPARITIVE 
SAMPLE SIZE:   100 
PERIOD OF STUDY: JULY 2015-JUNE 2016 
INCLUSION CRITERIA 
• Patients Of age  group- 18 to 35, diagnosed  as severe PRE 
ECLAMPSIA  with BP under control  
EXCLUSION CRITERIA FOR EXPECTANT MANAGEMENT     
(AT THE TIME OF DIAGNOSIS) 
• Uncontrolled hypertension with antihypertensives 
• Signs of imminent eclampsia 
• AP Eclampsia 
• Abruptio placenta 
• Deterioration of renal function, Liver function 
• oliguria 
• HELLP syndrome 
• Abnormal fundus examination 
• IUGR 
• Abnormal Doppler study 
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A  COMPARITIVE STUDY WILL BE CONDUCTED BETWEEN 
JULY 2015 to JUNE 2016 
 
GROUP 1: 50 PATIENTS WITH SEVERE PRE ECLAMPSIA 
PRESENTING BETWEEN 30-34 WEEKS TERMINATED 
ACTIVELY  
GROUP 2: 50 PATIENTS WITH SEVERE PRE ECLAMPSIA, 
MANAGED CONSERVATIVELY TILL 34 WEEKS PROVIDED 
BP IS UNDER CONTROL (with normal liver, renal function) 
Procedure: 
• All the pregnant women attending antenatal op are screened for 
hypertension. 
• Patients with severe PIH, with BP- .≥160/110, urine albumin ≥2+ 
are hospitalised. 
• On admission, thorough clinical examination including general 
examination, built, nourishment, height, weight, BP, pulse, along 
with pallor, pedal edema. Weight gain is noted. 
• CVS, RS examination done. 
• Abdominal examination done for height of uterus in weeks, lie of 
the fetus, presentation, position of the fetus, fetal heart rate. 
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• Blood investigations including CBC, RFT, LFT, SERUM URIC 
ACID done. 24 hr urine protein excretion evaluated, Fundus 
examination done. USG with Doppler done for fetal wellbeing. 
•  Treatment included rest, Anti hypertensives for BP control, 
Inj.dexamethasone for fetal lung maturiy. 
• Maternal complications in both groups are compared. 
• Fetal outcome in both groups including birth weight, incidence of 
NICU admissions are compared between both groups studied. 
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DATA ANALYSIS 
 
Table 1: Maternal age 
Age EXPECTANT 
(n - 50) 
ACTIVE 
(n-50) 
TOTAL 
 No. % No. %  
<20 9 18% 7 14% 16 
21-30 29 58% 25 50% 54 
>30 12 24% 18 36% 30 
 
Most no. of women are in age group 21-30 (54%) 
Mean age= 26 years 
Range = 18 to 36 years 
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Table 2: Gravida 
GRAVIDA EXPECTANT 
      (n-50) 
ACTIVE 
(n-50) 
TOTAL 
 No. % No. %  
Primi 30 60% 32 64% 62 
multi 20 40% 18 36% 38 
 
most women are Primi (62%) 
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Table 3: Gestational age 
GA EXPECTANT 
       (n-50) 
ACTIVE 
         (n-50) 
TOTAL 
 No. % No. %  
30-32 weeks 35 70% 33 66% 68 
32-34 weeks 15 30% 17 34% 32 
 
Only women with gestational ages between 30 and 34 weeks were 
selected for the study. Mean gestational age = 31 weeks 
 
 
 
 
 
 
 
67 
 
TABLE 3: BOOKED OR UNBOOKED 
 
GA EXPECTANT (n-50) ACTIVE 
(n-50) 
 No. % No. % 
Booked 50 100% 48 96% 
Unbooked 0  2 4% 
 
On the whole, 98 patients were booked. Only 2 were unbooked 
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TABLE 4: GESTATIONAL AGE AT DELIVERY 
 
GA EXPECTANT 
     (n-50) 
ACTIVE 
        (n-50) 
TOTAL 
 No. % No. %  
30-32 weeks 17 34% 29 58% 46 
32-34 weeks 33 66% 21 42% 54 
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Table 5: STEROID INJECTION GIVEN/NOT 
Steroid given EXPECTANT 
      (n-50) 
ACTIVE 
        (n-50) 
TOTAL 
 no % No %  
yes 50 100% 33 66% 83 
no 0  17 34% 17 
 
All women managed expectantly were given steroid injection or fetal 
maturity. Whereas only 66% required steroid in active group 
 
STEROID INJECTION 
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TABLE 7: INDICATION FOR TERMINATION 
 
GA EXPECTANT  
      (n-50) 
 No. % 
FETAL 21 42% 
MATERNAL 29 58% 
 
 
Maternal indication accounts for 58% of the cases while Fetal indication 
for 42% 
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Table 8: INDICATION FOR TERMINATION 
Complication Expectant 
Abnormal coagulation profile 1 
Abnormal CTG 4 
Abnormal Doppler 0 
Abnormal platelet count 1 
Abruption 4 
Acute kidney injury 2 
Eclampsia 1 
Fetal distress 0 
Fundus changes 2 
HELLP 0 
Imminent eclampsia 10 
IUD 1 
IUGR 5 
Oligohydramnios 10 
Pulmonary edema 1 
Uncontrolled BP 8 
Total 50 
 
Table 9: MODE OF DELIVERY: 
Mode Expectant 
 (n-50) 
Active  
          (n-50) 
total 
 no % No %  
vaginal 31 62% 34 68% 65 
caesarean 19 38% 16 32% 35 
 
Chi square= 0.396 
Degree of freedom= 1 
P=0.53 (insignificant) 
Total LSCS= 35 
Mode of delivery has no significant influence over the fetal / maternal 
outcome. 
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Table 10: MATERNAL OUTCOME 
  
 
Total Expectant Active 
 ABRUPTION Count 4 5 9 
% 23.5% 38.5% 30.0% 
ACUTE KIDNEY 
INJURY 
Count 2 1 3 
% 11.8% 7.7% 10.0% 
ANTEPARTUM 
ECLAMPSIA 
Count 3 2 5 
% 17.6% 15.4% 16.7% 
DIC Count 1 0 1 
% 5.9% 0.0% 3.3% 
HELLP SYNDROME Count 2 2 4 
% 11.8% 15.4% 13.3% 
INTRAPARTUM 
ECLAMPSIA 
Count 1 0 1 
% 5.9% 0.0% 3.3% 
POSTPARTUM 
ECLAMPSIA 
Count 1 0 1 
% 5.9% 0.0% 3.3% 
PRES Count 1 1 2 
% 5.9% 7.7% 6.7% 
PULMONARY EDEMA Count 2 2 4 
% 11.8% 15.4% 13.3% 
Total Count 17 13 30 
% 100.0% 100.0% 100.0% 
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In our study there was no maternal mortality. Maternal morbidity was 
seen in 30%. Abruption was the highest accounting to 9 patients, 
followed by eclampsia in 7.  Other complications were HELLP, 
pulmonary edema, PRES, DIC and acute kidney injury 
Chi Square= 3.163 
Degree of Freedom= 8 
Significance- 0.923 
The mode of management has no influence over  maternal outcome 
 
 
 
0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% 40.0%
ABRUPTION
ACUTE KIDNEY INJURY
ANTEPARTUM ECLAMPSIA
DIC
HELLP SYNDROME
INTRAPARTUM ECLAMPSIA
POSTPARTUM ECLAMPSIA
PRES
PULMONARY EDEMA
23.5%
11.8%
17.6%
5.9%
11.8%
5.9%
5.9%
5.9%
11.8%
38.5%
7.7%
15.4%
0.0%
15.4%
0.0%
0.0%
7.7%
15.4%
Maternal outcome
Active Expectant
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Table 11: FETAL OUTCOMES 
Outcome expectant Active total 
 no % no %  
Total birth 50  50  100 
      
Live 45 90% 44 88% 89 
Stillbirth 2 4% 4 8% 6 
IUD 3 6% 2 4% 5 
PND 5 10% 13 26% 18 
 
Perinatal loss= 10% in expectant and 26% in active 
Total stillborn=6 
Total PND= 18 
Chi square 4.336 
Degree of freedom 1 
Significance 0.037 
Expectant management has a significant effect on the Fetal outcome with 
p=0.037 
Babies born of expectant management have better survival than those 
managed actively 
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Table 12: NICU Admission: 
NICU 
admission 
Expectant  
   (n-50) 
Active 
        (n-50) 
Total  
 No. % No. %  
Yes  33 66% 40 80% 73 
No  17 34% 10 20% 27 
 
Chi square= 2.486 
Degree of feedom = 1 
P=0.115 
80% of babies born to actively managed mothers required NICU 
admission 
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TABLE 13: BIRTH WEIGHT  
 EXPECTANT 
(n-50) 
ACTIVE 
(n-50) 
TOTAL 
Kg No.  % N0. %  
1-1.5 9 18% 18 36% 27 
1.5-2 24 48% 23 46% 47 
2-2.5 17 34% 9 18% 26 
 
Max. birth weight = 2.4 kg 
Mean BW= ACTIVE- 1.66 KG 
  EXPECTANT – 1.89 KG 
Chi square=5.483 
Degree of freedom=2 
Significance=0.064 
Babies delivered by expectant management have higher mean birth 
weight (1.89kg) than those actively delivered (1.66kg) 
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TABLE 14: NO OF DAYS GAINED IN EXPECTANT 
MANAGEMENT 
Days Cases 
(n-50) 
% 
<5 22 44% 
5-8 13 26% 
9-12 12 24% 
13-20 2 4% 
>20 1 2% 
 
Max no of days gained =  24 
Mean= 6.8 days 
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TABLE 16: APGAR SCORE AT 5 MIN 
 EXPECTANT 
(n-50) 
ACTIVE 
(n-50) 
TOTAL 
APGAR No.  % No. %  
≤ 5 17 34% 24 48% 41 
>5 33 66% 26 52% 59 
 
Active and expectant management did not have much impact on the 
contribution to the APGAR score 
Chi square = 2.06 
Degree of freedom = 1 
P= 0.155 
 
 
The collected data were analysed with IBM.SPSS statistics 
software 23.0 Version.To describe about the data descriptive statistics 
frequency analysis, percentage analysis were used for categorical 
variables and the mean & S.D were used for continuous variables. To find 
the significant difference between the bivariate samples in Independent 
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groups the Unpaired sample t-test was used.To find the significance in 
categorical data Chi-Square test was used. In both the above statistical 
tool the probability value .05 is considered as significant level.  
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DISCUSSION 
Age: 
54% of the women in the study were of ages between 21 and 30 years  
with mean age of 26 years. This result correlates with the studies of 
Moodleyand studies done by Brown MA and Buddle ML, D.R.Hall 
(mean age was 26 years).  
Parity: 
Preeclampsia is common in primi. 62% of our study group was primi. 
Brown MA and Buddle ML said preeclampsia is predominant in 
nulliparous. 
MATERNAL OUTCOMES: 
In our study there was no maternal mortality. Maternal morbidity was 
seen in 30%. abuption was the highest accounting to 9 patients, followed 
by eclampsia in 7.  Other complications were HELLP, pulmonary edema, 
PRES, DIC and acute kidney injury 
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Study Abruption Pulmonary 
edema 
HELLP eclampsia Renal 
failure 
DR Hall [25] 20% 2% 5% 1.2% 0.3% 
Murphy DJ 
[23] 
1.5% - 21% 1.4% 1.3% 
Vissur and 
Wallenberg 
[22] 
5% - - 2% - 
Our study 9% 4% 4% 7% 3% 
 
TERMINATION 
Indication of Termination  is distributed as follows 
Study Maternal indication Fetal indication 
Blackwell Sc[24] 80% 20% 
Hall DR, Odendaal 55% 45% 
Our study 58% 42% 
 
Maternal indication was the most common cause for termination of 
pregnancy in 58% and the fetal cause in 42%.  
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Mode of delivery 
Delivery is the ultimate cure for preeclampsia. LSCS was done in 
35 women and vaginal in 65 women in our study. Mode of delivery had 
no influence over fetal outcome 
Study Vaginal caesarean 
Hall et al 18.5% 81.5% 
Murphy DJ 20% 80% 
Nasser et al[26] 48.3% 51.7% 
Railton and Allen[27] 25% 75% 
Our study 65% 35% 
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PERINATAL OUTCOME 
Prolongation of pregnancy 
Study Mean prolongation 
Odendall et al 7.1 days 
Vissur w, wallberg 14 days 
Railton and allen 11.2 days 
Olah KS 9.5 days 
Murphy DJ 14 days 
Our study 6.8 days 
 Our study correlates with Odendaal et al.  
mean no of days prolonged is 6.8 days with range from 1 to 24 days 
Perinatal Mortality 
In expectantly managed group 
Study % loss 
Railton and allen 24.5% 
Hall Dr 24% 
Murphy DJ 30% 
Odendaal and pattison 22.3% 
Our study 10% 
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In actively managed group perinatal mortality was 13 (26%). Overall 
perinatal mortality was 29% 
Birth weight 
Study Active expectant 
Sibai et al[28] 1.2kg 1.62 kg 
Our study 1.6 kg 1.8 kg 
 
Survival rate 
Study Active expectant 
Sibai et al 24% 65% 
HALL DR 70% 94% 
Our study 70% 84% 
In Our study there was higher survival rate in babies born of expectantly 
managed 
Neonatal Hospitalisation 
Study Active expectant 
Olah KS  64.3% 28.6% 
Sibai et al 100% 76% 
Our study 80% 66% 
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Babies born from mothers in expectant management have higher survival 
rate and required lesser hospitalization than those from actively managed 
cases. 
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SUMMARY 
 
• Total no of patients = 100 
• Actively managed = 50 
• Expectantly managed = 50 
• Mostly are in ages between 21-30 years 
• Mostly primi (62%) 
• Mean gestational age = 31 weeks 
• There was no maternal death and 7 cases of eclampsia                                      
(5 in expectant & 2 in active) 
• Most women in active management delivered by vaginal 
delivery(65%) 
• Termination of pregnancy was due to maternal indication in 58% 
and fetal in 42% 
• 29% perinatal death was recorded 
• Mean birthweight was 1.6kg in active and 1.8 kg in expectant 
group 
• Maximum birth weight was 2.4kg 
• Maximum prolongation was 24  days 
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CONCLUSION 
 
Severe preeclampsia is associated with significant maternal and 
fetal complications. Decision regarding pregnancy termination is to be 
taken on the grounds of both maternal and fetal factor. The expectant 
management of severe preclampsia results in a good fetal outcome for 
1. Higher birth weight 
2.  Lesser neonatal complications 
But this must be weighed against the risk of maternal 
morbidity.Hence they should be carried out only in tertiary care centres 
where there is experienced obstetrician and neonatologist are available 
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 PROFORMA 
 
 
Name : 
Age: 
Gravida: 
ht : 
weight: 
 
 
Complaints: 
• Present H/o: 
• Period Of Amenorrhea  
• Edema feet 
• Headache 
• Oliguria  
• Pain abdomen 
• Vomiting  
• Blurring of vision 
• Palpitation  
 
Past H/o: 
• H/o Preeclampsia in previous pregnancy 
Menstrual h/o 
Marital H/o: 
Medical / Surgical H/o: 
• H/o Epilepsy, Head injury, Neurologicaldisorder. 
Family H/o:  H/o PE in Mother/Sister 
Personal H/o: 
IP No:  
Occupation: 
LMP: 
EDD: 
Blood group: 
Booked / Not: 
 
  
General Examination: 
 Temp 
 CVS 
 PR  
 RS 
 BP 
 Cns 
 Anaemia 
 
Investigations: 
CHG: 
• Hb 
• Blood Urea 
• Blood glucose 
• PCV 
• TC 
 
Urine : 
• Alb 
• Deposits  
• Sugar 
LFT:  
USG:  
ECG: 
 
 
 
• Fibrinogen 
• Platelets  
• Uric Acid 
• Electrolytes 
• Creatinine 
 
• Pupils 
• Edema  
• P/A 
• P/V 
 
 Gravidogram: Date urine alb wt. SFH AC BP . Imminent symptoms 
1. Mode of induction 
2. Indication of termination : Maternal / Fetal 
3. Vaginal delivery / LSCS 
Indication of LSCS: 
4. Latency Interval 
5. Baby alive/dead 
• Term/preterm 
• Cried/not 
• Birth weight 
• Distress/Not 
• Admitted / not 
6. Intrapartum / Postpartum complications 
7. Follow up: 
• NICU stay 
• Neonatal complications 
• Discharged alive / not. 
EXPECTANT MANAGEMENT
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LAKSHMI 20 PRIMI BOOKED 30W2 YES 4 30W6D MATERNAL ABRUPTION LSCS ABRUPTION 1.2 4 YES PND
NANDHINI 32 MULTI BOOKED 31W YES 13 32W6D MATERNAL
IMMINENT 
ECLAMPSIA VD NORMAL 1.5 7 YES NORMAL
REKA 21 PRIMI BOOKED 31W2D YES 9 32W2D FETAL IUGR VD NORMAL 1.6 6 YES NORMAL
PRIYA 24 PRIMI BOOKED 30W2 YES 1 30W1D MATERNAL ABRUPTION LSCS ABRUPTION 1.3 7 YES NORMAL
OVIYA 18 MULTI BOOKED 32W YES 10 32W3D MATERNAL ECLAMPSIA LSCS
M 
ECLAMPSIA 2 4 YES PND
JOTHI 33 MULTI BOOKED 31W YES 7 32W FETAL ABNORMAL CTG LSCS NORMAL 2.1 6 YES NORMAL
DEEPA 25 PRIMI BOOKED 33W YES 2 33W2D FETAL OLIGOHYDRAMNIOS LSCS NORMAL 2.2 7 NO NORMAL
MANJU 16 PRIMI BOOKED 31W5D YES 5 32W4D MATERNAL
IMMINENT 
ECLAMPSIA VD NORMAL 2 8 YES NORMAL
AMUTHA 20 MULTI BOOKED 33W YES 1 33W1D MATERNAL
ABNORMAL 
PLATELET COUNT VD DIC 1.9 8 YES NORMAL
KAMALI 28 MULTI BOOKED 30W YES 22 33W1D FETAL IUGR VD NORMAL 1.5 6 YES NORMAL
POONGODI 21 PRIMI BOOKED 32W YES 7 33W MATERNAL
IMMINENT 
ECLAMPSIA LSCS
POSTPARTUM 
ECLAMPSIA 1.9 8 YES NORMAL
SELVI 18 PRIMI BOOKED  31W2D YES 3 31W5D MATERNAL FUNDUS CHANGES VD NORMAL 1.7 7 YES NORMAL
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SATHYA 29 MULTI BOOKED 31W2D YES 2 31W4D FETAL IUGR VD NORMAL 1.5 0 NO
STILL 
BORN
NITHYA 22 PRIMI BOOKED 32W4D YES 9 33W6D FETAL OLIGOHYDRAMNIOS LSCS NORMAL 2.2 6 NO NORMAL
SRI 24 PRIMI BOOKED 33W YES 4 33W4D FETAL ABNORMAL CTG LSCS NORMAL 2.2 6 NO NORMAL
SEVVANTHI 24 MULTI BOOKED 33W YES 2 33W2D MATERNAL
 
COAGULATION 
PROFILE VD
HELLP 
SYNDROME 2.1 7 NO NORMAL
REVATHI 26 MULTI BOOKED 31W2D YES 5 32W FETAL IUGR LSCS NORMAL 1.8 6 YES NORMAL
SASI 28 MULTI BOOKED 32W YES 3 32W3D MATERNAL
IMMINENT 
ECLAMPSIA VD NORMAL 2 8 YES NORMAL
BUVANA 35 PRIMI BOOKED 30W2D YES 12 32W MATERNAL ABRUPTION LSCS ABRUPTION 2.1 6 NO NORMAL
BARATHI 20 PRIMI BOOKED 33W YES 1 33W1D FETAL IUD LSCS NORMAL 2.1 0 NO IUD
GOKILA 22 MULTI BOOKED 30W1D YES 18 32W5D MATERNAL
IMMINENT 
ECLAMPSIA VD NORMAL 2 8 YES NORMAL
MANI 36 PRIMI BOOKED 32W2D YES 2 32W4D MATERNAL PULMONARY EDEMA LSCS
PULMONARY 
EDEMA 2 7 YES NORMAL
ABIRAMI 24 MULTI BOOKED 31W YES 9 32W2D MATERNAL FUNDAL CHANGES VD NORMAL 1.9 5 YES NORMAL
ANITHA 31 PRIMI BOOKED 33W YES 5 33W5D FETAL IUGR LSCS NORMAL 1.9 5 YES NORMAL
PADMA 26 PRIMI BOOKED 31W2D YES 12 33W1D MATERNAL
IMMINENT 
ECLAMPSIA VD
M 
ECLAMPSIA 2.2 4 NO NORMAL
SINDHU 30 PRIMI BOOKED 31W4D YES 1 31W5D MATERNAL
ACUTE KIDNEY 
INJURY LSCS
 
KIDNEY 
INJURY 1.9 7 YES NORMAL
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SRIDIVYA 18 MULTI BOOKED 32W1D YES 6 33W MATERNAL UNCONTROLLED BP VD
HELLP 
SYNDROME 2.2 8 NO NORMAL
NANDHINI 36 PRIMI BOOKED 32W YES 7 33W FETAL OLIGOHYDRAMNIOS VD NORMAL 2 8 YES NORMAL
DEVI 29 PRIMI BOOKED 32W YES 5 32W5D FETAL OLIGOHYDRAMNIOS VD NORMAL 2.1 4 NO PND
KANAG 32 MULTI BOOKED 30W YES 9 31W2D MATERNAL
IMMINENT 
ECLAMPSIA VD NORMAL 1.8 7 YES NORMAL
RAMYA 22 PRIMI BOOKED 30W2D YES 12 32W FETAL OLIGOHYDRAMNIOS VD NORMAL 1.5 0 YES IUD
VIDYA 18 PRIMI BOOKED 32W YES 6 32W6D MATERNAL UNCONTROLLED BP LSCS PRES 1.9 0 YES NORMAL
KALA 19 MULTI BOOKED 33W1D YES 2 33W3D FETAL OLIGOHYDRAMNIOS VD NORMAL 2.5 8 YES NORMAL
ALMELU 21 PRIMI BOOKED 30W YES 7 31W FETAL OLIGOHYDRAMNIOS VD NORMAL 1.6 6 NO NORMAL
GETHA 35 PRIMI BOOKED 31W YES 5 31W5D FETAL OLIGOHYDRAMNIOS VD NORMAL 1.9 2 YES NORMAL
REVATHY 30 PRIMI BOOKED 31W YES 10 33W3D MATERNAL UNCONTROLLED BP VD
PULMONARY 
EDEMA 2 6 YES NORMAL
MAHA 36 MULTI BOOKED 33W YES 6 33W6D MATERNAL
IMMINENT 
ECLAMPSIA VD NORMAL 2.2 7 NO NORMAL
VENI 22 PRIMI BOOKED 31W3D YES 11 34W FETAL ABNORMAL CTG LSCS NORMAL 2.5 1 YES PND
TAMILSELVI 33 MULTI BOOKED 30W YES 1 30W1D FETAL
ACUTE KIDNEY 
INJURY LSCS
 
KIDNEY 
INJURY 1.3 3 YES NORMAL
MLLIGA 24 PRIMI BOOKED 30W3D YES 12 32W1D MATERNAL
IMMINENT 
ECLAMPSIA LSCS NORMAL 1 8 YES NORMAL
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PAVITHRA 31 PRIMI BOOKED 30W2D YES 7 31W2D FETAL OLIGOHYDRAMNIOS VD NORMAL 1.5 2 YES PND
KRIPA 21 PRIMI BOOKED 32W1D YES 5 32W5D MATERNAL UNCONTROLLED BP VD NORMAL 1.6 8 YES NORMAL
VIJAYA 30 MULTI BOOKED 31W YES 7 32W MATERNAL UNCONTROLLED BP VD
M 
ECLAMPSIA 1.75 7 YES NORMAL
DEEPA 21 PRIMI BOOKED 32W2D YES 8 33W3D FETAL ABNORMAL CTG LSCS NORMAL 2.1 7 YES NORMAL
JOTHI 30 PRIMI BOOKED 30W1D YES 12 32W6D FETAL OLIGOHYDRAMNIOS VD NORMAL 2 0 NO
STILL 
BORN
JESI 22 MULTI BOOKED 32W1D YES 5 32W6D MATERNAL
IMMINENT 
ECLAMPSIA VD NORMAL 2.2 7 NO NORMAL
SUMATHI 30 PRIMI BOOKED 31W YES 7 32W MATERNAL UNCONTROLLED BP VD NORMAL 2 6 NO NORMAL
AYESHA 23 MULTI BOOKED 33W YES 5 33W5D MATERNAL ABRUPTION VD ABRUPTION 2.4 0 NO IUD
VENNILA 34 PRIMI BOOKED 31W5D YES 8 32W6D MATERNAL UNCONTROLLED BP VD NORMAL 2 0 YES NORMAL
POOJA 24 MULTI BOOKED 31W YES 7 32W MATERNAL UNCONTROLLED BP VD
M 
ECLAMPSIA 2.1 7 NO NORMAL
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ACTIVE MANAGEMENT
ANU 21 PRIMI BOOKED 30W YES 30W2D MATERNAL _ VD NORMAL 1 4 YES PND
SOUNDARYA 21 PRIMI BOOKED 31W3D NO 31W3D MATERNAL ABRUPTION VD ABRUPTION 1.2 0 NO
STILL 
BORN
RAMYA 31 PRIMI UNBOOKED 31W YES 31W2D MATERNAL _ VD NORMAL 1.2 4 YES NORMAL
VEENA 22 MULTI BOOKED 31W3D YES 31W5D MATERNAL _ VD NORMAL 1.2 4 YES NORMAL
SUJATAH 23 PRIMI BOOKED 32W YES 32W1D MATERNAL _ VD NORMAL 1.8 4 YES NORMAL
ARYA 17 PRIMI BOOKED 32W2D NO 32W2D MATERNAL ABRUPTION LSCS ABRUPTION 1.8 6 NO PND
ANJALI 20 PRIMI BOOKED 32W YES 32W MATERNAL _ VD NORMAL 1.7 6 YES NORMAL
RAJI 32 MULTI BOOKED 31W5D YES 31W6D MATERNAL _ VD NORMAL 1.8 6 YES NORMAL
ARUNA 24 PRIMI BOOKED 30W2D YES 30W4D FETAL OLIGOHYDRAMNIOS VD NORMAL 1.1 3 YES PND
ARCHANA 25 MULTI BOOKED 33W4D YES 33W6D MATERNAL _ VD NORMAL 2 7 YES NORMAL
VIDHYA 32 PRIMI BOOKED 31W2D NO 31W2D MATERNAL HELLP SYNDROME VD
HELLP 
SYNDROME 1.3 3 YES NORMAL
SAROJA 26 MULTI BOOKED 33W5D YES 34W MATERNAL _ VD NORMAL 2.1 6 YES NORMAL
MANISHA 33 PRIMI UNBOOKED 31W5D YES 32W MATERNAL _ VD NORMAL 1.8 6 YES NORMAL
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SOUMIYA 27 MULTI BOOKED 30W3D YES 30W5D FETAL OLIGOHYDRAMNIOS VD NORMAL 1.3 0 NO
STILL 
BORN
SURYA 34 PRIMI BOOKED 3W5D YES 32W MATERNAL _ VD NORMAL 1.7 6 YES NORMAL
DEEPIKA 28 MULTI BOOKED 33W2D NO 33W2D MATERNAL
ANTEPARTUM 
ECLAMPSIA LSCS
M 
ECLAMPSIA 2.1 6 YES NORMAL
ANBU 20 PRIMI BOOKED 31W2D YES 31W3D MATERNAL _ VD NORMAL 1.8 0 NO
STILL 
BORN
TAMILSELVI 22 MULTI BOOKED 31W5D YES 32W MATERNAL _ VD NORMAL 1.9 8 YES NORMAL
SELVI 16 PRIMI BOOKED 32W2D NO 32W2D MATERNAL
ACUTE KIDNEY 
INJURY LSCS
 
KIDNEY 
INJURY 2 8 YES NORMAL
THIRU 36 PRIMI BOOKED 30WD NO 30W3D MATERNAL ABRUPTION LSCS ABRUPTION 1.1 3 NO PND
ABIRAMI 24 PRIMI BOOKED 32W YES 32W2D MATERNAL _ LSCS NORMAL 1.8 6 YES NORMAL
APSARA 37 PRIMI BOOKED 33W YES 33W1D MATERNAL _ VD NORMAL 2 6 YES NORMAL
RAMELA 26 PRIMI BOOKED 30W YES 30W2D FETAL
ABNORMAL 
DOPPLER VD NORMAL 1 2 NO PND
SINDU 33 MULTI BOOKED 32W1D YES 32W3D MATERNAL _ LSCS NORMAL 1.8 6 YES NORMAL
NITHYA 28 PRIMI BOOKED 30W5D NO 31W MATERNAL PULMONARY EDEMA LSCS
PULMONARY 
EDEMA 1.2 0 NO
STILL 
BORN
KAVITHA 31 PRIMI BOOKED 31W3D YES 31W5D MATERNAL _ VD NORMAL 1.8 6 YES NORMAL
SUGANYA 22 PRIMI BOOKED 33W2D YES 33W4D MATERNAL _ VD NORMAL 2.1 6 YES NORMAL
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AGALYA 21 PRIMI BOOKED 30W2D NO 30W2D FETAL OLIGOHYDRAMNIOS VD NORMAL 1.1 3 YES PND
VIJAYA 17 MULTI BOOKED 30W5D YES 31W MATERNAL _ LSCS NORMAL 1.3 4 YES PND
PAPPATHI 30 PRIMI BOOKED 31W6D NO 31W6D MATERNAL
ANTEPARTUM 
ECLAMPSIA LSCS
M 
ECLAMPSIA 1.5 6 YES NORMAL
VELLACHI 31 MULTI BOOKED 35W5D YES 34W MATERNAL _ VD NORMAL 2.4 8 YES NORMAL
THANGAM 21 PRIMI BOOKED 31W6D YES 32W1D MATERNAL - VD NORMAL 2 8 YES NORMAL
ARUNA 31 MULTI BOOKED 32W2D NO 32W2D MATERNAL PULMONARY EDEMA LSCS
PULMONARY 
EDEMA 1 4 YES PND
ARIVU 22 PRIMI BOOKED 30W6D YES 31W1D MATERNAL _ VD NORMAL 1.8 6 YES NORMAL
NIVIRA 31 MULTI BOOKED 32W1D YES 32W3D MATERNAL _ VD NORMAL 2 6 YES NORMAL
SALMA 22 PRIMI BOOKED 31W NO 31W FETAL
ABNORMAL 
DOPPLER LSCS NORMAL 1.3 4 YES PND
KUMARI 30 MULTI BOOKED 33W2D YES 33W4D MATERNAL _ VD NORMAL 2.1 8 NO NORMAL
GEETHA 23 PRIMI BOOKED 31W3D YES 31W5D MATERNAL _ VD NORMAL 1.9 6 YES NORMAL
PREMA 31 MULTI BOOKED 31W3D NO 31W3D MATERNAL HELLP SYNDROME LSCS
HELLP 
SYNDROME 1.7 4 YES NORMAL
SUGNYA 22 PRIMI BOOKED 31W5D YES 32W MATERNAL _ VD NORMAL 1.8 6 YES NORMAL
SARMAN 32 MULTI BOOKED 33W NO 33W FETAL IUD VD NORMAL 2.1 0 NO IUD
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FATHMA 21 PRIMI BOOKED 30W3D NO 30W3D MATERNAL ABRUPTION LSCS ABRUPTION 1.1 3 YES PND
PARVATHY 20 PRIMI BOOKED 31W6D NO 31W6D MATERNAL UNCONTROLLED BP LSCS PRES 1.6 4 YES NORMAL
SUJITHA 20 PRIMI BOOKED 31W3D YES 33W MATERNAL _ VD NORMAL 2.1 4 YES PND
THARANI 31 MULTI BOOKED 33W YES 33W2D MATERNAL _ VD NORMAL 2.1 6 YES NORMAL
NITHYA 21 PRIMI BOOKED 32W3D NO 32W5D MATERNAL ABRUPTION LSCS ABRUPTION 1.8 0 NO IUD
SELVI 33 MULTI BOOKED 30W5D NO 30W5D FETAL FETAL DISTRESS LSCS NORMAL 1.2 4 YES PND
MANI 22 PRIMI BOOKED 31W5D YES 32W1D MATERNAL _ VD NORMAL 2 8 YES NORMAL
RAJI 34 MULTI BOOKED 33W2D YES 33W4D MATERNAL _ VD NORMAL 2.1 8 YES NORMAL
SUGANYA 31 PRIMI BOOKED 31W3D YES 31W5D MATERNAL _ VD NORMAL 1.4 3 YES PND
